Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18'25 years: Results from a randomized controlled trial

International Journal of Cancer

Volumn 135, Issue 11, 2014, Pages 2612-2622

  Zhu, Feng Cai ^a   Chen, Wen ^b   Hu, Yue Mei ^a   Hong, Ying ^c   Li, Juan ^d   Zhang, Xun ^b   Zhang, Yi Ju ^a   Pan, Qin Jing ^b   Zhao, Fang Hui ^b   Yu, Jia Xi ^e   Zhang, Yan Shu ^f   Yang, Xiaoping ^g   Zhang, Cheng Fu ^h   Tang, Haiwen ⁱ   Zhang, Helen ⁱ   Lebacq, Marie ^j   David, Marie Pierre ^j   Datta, Sanjoy K ^j   Struyf, Frank ^j   Bi, Dan ^j   Descamps, Dominique ^j   more..

^a JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b CANCER HOSPITAL   (China)

^c THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^d NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^e CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^f Binhai Center for Disease Prevention and Control   (China)

^g Jintan Center for Disease Control and Prevention   (China)

^h Lianshui County Center for Disease Control and Prevention   (China)

ⁱ GLAXOSMITHKLINE   (China)

^j GSK   (Belgium)

more..

Author keywords

China; Efficacy; Human papillomavirus vaccine; Immunogenicity; Safety

Indexed keywords

VIRUS ANTIBODY; VIRUS DNA; WART VIRUS VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; PAPILLOMAVIRUS INFECTION; PERSISTENT INFECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; TREATMENT DURATION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; ADOLESCENT; CANCER GRADING; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHINA; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHINA; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; NEOPLASM GRADING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84921694275     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28897     Document Type: Article

References (35)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010. Available at http://globocan.iarc.fr. Accessed on: 7 August 2013.
2. Zhao FH, Lewkowitz AK, Hu SY, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer 2012; 131:2929-38.
3. Bao YP, Li N, Smith JS, et al. Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis. Int J STD AIDS 2008;19:106-11.
4. Chen W, Zhang X, Molijn A, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control 2009;20:1705-13.
5. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927-35.
6. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 viruslike-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369: 2161-70.
7. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)216/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374: 301-14.
8. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009;5:332-40.
9. The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)216/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374:1975-85.
10. Zhu FC, Li CG, Pan HX, et al. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial. Chin J Cancer 2011;30:559-64.
11. Zhu FC, Li CG, Gu SK, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years. Abstract presented at the AOGIN (Asia-Oceania Research Organisation in Genital Infection and Neoplasia) Interim Meeting, Bali, Indonesia, 2011.
12. Apgar BS, Zoschnick L, Wright TC, Jr. The 2001 Bethesda System terminology. Am Fam Physician 2003;68:1992-8.
13. van Doorn LJ, Molijn A, Kleter B, et al. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006;44:3292-8.
14. Dessy FJ, Giannini SL, Bougelet CA, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008;4:425-34.
15. Dragalin V, Fedorov V, Cheuvart B. Statistical approaches to establishing vaccine safety. Stat Med 2002;21:877-93.
16. Zhao FH, Zhu FC, Chen W, et al. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial. Int J Cancer. 2014 Apr 17 doi: 10.1002/ijc.28896. [Epub ahead of print]
17. United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2012 Revision. Available at: http://esa.un.org/wpp/Excel-Data/population.htm. Accessed on 20 November 2013.
18. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
19. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
20. Herrero R, Hildesheim A, Rodriguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008;26:4795-808.
21. World Health Organization Expert Committee on Biological Standardization. Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines. WHO, Geneva, Oct 23-27, 2006. Available at http://www.who.int/biologicals/publications/trs/areas/vaccines/human-papillomavirus/HPVg%20Final%20BS%202050%20.pdf. Accessed on 7 August 2013.
22. Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008;168:123-37.
23. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-9.
24. Renshaw AA, Davey DD, Birdsong GG, et al. Precision in gynecologic cytologic interpretation: a study from the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med 2003;127:1413-20.
25. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUSLSIL Triage Study. JAMA 2001;285:1500-5.
26. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of typespecific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9.
27. Castle PE, Solomon D, Schiffman M, et al. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005;97: 1066-71.
28. Castle PE, Rodriguez AC, Burk RD, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 2009;339:b2569.
29. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:89-99.
30. Wheeler CM, Castellsague X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:100-10.
31. Konno R, Tamura S, Dobbelaere K, et al. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 doubleblind, randomized controlled trial. Int J Gynecol Cancer 2010;20:847-55.
32. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
33. Naud P, Roteli-Martins CM, De Carvalho N, et al. HPV-16/18 vaccine: sustained immunogenicity and efficacy up to 9.4 years. Abstract presented at 27th International Papillomavirus Conference and Clinical Workshop, Berlin, Germany, 2011. Available at http://www.hpv2011. org/pics/1/4/Abstract%20Book%202%20APSC%20 WEBB%20110922.pdf. Accessed on 7 August 2013.
34. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743-53.
35. Zhao FH, Tiggelaar SM, Hu SY, et al. A multicenter survey of age of sexual debut and sexual behavior in Chinese women: Suggestions for optimal age of human papillomavirus vaccination in China. Cancer Epidemiol 2012;36:384-90.